Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events-Reference-Cited by-同舟云学术

Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events

Published:2024-06 Issue:6 Volume:6 Page:101065
ISSN:2589-5559
Container-title:JHEP Reports
language:en
Short-container-title:JHEP Reports

Author:

Ben Khaled Najib^ORCID,Möller Marie,Jochheim Leonie S.,Leyh Catherine,Ehmer Ursula^ORCID,Böttcher Katrin^ORCID,Pinter Matthias^ORCID,Balcar Lorenz^ORCID,Scheiner Bernhard,Weich Alexander,Leicht Hans Benno,Zarka Valentina,Ye Liangtao,Schneider Julia,Piseddu Ignazio^ORCID,Öcal Osman,Rau Monika^ORCID,Sinner Friedrich^ORCID,Venerito Marino^ORCID,Gairing Simon Johannes^ORCID,Förster Friedrich^ORCID,Mayerle Julia^ORCID,De Toni Enrico N.^ORCID,Geier Andreas,Reiter Florian P.

Publisher

Elsevier BV

Reference34 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study;Park;Liver Int,2015

3. Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study;De Toni;Gut,2020

4. Hepatocellular carcinoma;Llovet;Nat Rev Dis Primers,2021

5. Advances in pharmacotherapy of hepatocellular carcinoma: a state-of-the-art review;Reiter;Dig Dis,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to: “Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC”;JHEP Reports;2024-08

2. Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC;JHEP Reports;2024-08